reported that a pharmacologic blockage of NLRP3 reduces liver inflammation and fibrosis in experimental NASH in mice (Mridha et al., 2017), indicating NLRP3 is a potential target of NASH treatment. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.